Conference Reports for NATAP
The Liver Meeting
Can HCV be eliminated among HIV---infected MSM in Berlin?
Modeling a setting with increasing incidence and high treatment rates
[from Jules: a key remaining barrier to eliminating HCV]
INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO, 2000-2015
High incidence of HCV reinfection in HIV-positive MSM in the DAA era
A Systematic HCV-RNA Screening in HIV+ MSM Reveals a High Number of Potential Transmitters: 5% HCV Prevalence, 17% acute HCV incidence, higher rates of condomless sex, IDU, syphillis
High prevalence of hepatitis C virus among HIV negative MSM in the Amsterdam PrEP project
HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B
Epidemiologic Impact of Expanding Chronic Hepatitis C (CHC) Treatment in People Who Inject Drug in the United States: A Mathematical Model Using Data From the C-EDGE CO-STAR Study
The Burden of HCV-Related Cirrhosis Among HIV/HCV Coinfected Individuals in Spain in the DAA Era: What will the battlefield look like once the battle is over?
Reported by Jules Levin
American Association for the Study of Liver Diseases (AASLD 2017), Washington, DC, October 20-24, 2017